Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665079 | 0.83 | MAPT (0.52) | MAPTTP53LMNACMA1GSK3A | |
| SCHEMBL17963973 | 0.83 | MAPT (0.52) | MAPTTP53LMNACMA1GSK3A | |
| SCHEMBL4295479 | 0.81 | MAPT (0.50) | MAPTTP53LMNACMA1GSK3A | |
| SCHEMBL28418647 | 0.79 | CA1 (0.56) | MAPTTP53LMNACMA1GSK3A | |
| SCHEMBL4474931 | 0.79 | MAPK14 (0.57) | MAPTTP53LMNACMA1MAPK14 | |
| SCHEMBL29348749 | 0.77 | MAPK14 (0.51) | MAPTTP53LMNACMA1GSK3A | |
| SCHEMBL2178268 | 0.76 | MAPK14 (0.82) | MAPTTP53LMNAMAPK14 | |
| SCHEMBL17392844 | 0.76 | MAPK14 (0.70) | MAPTTP53LMNACMA1MAPK14 | |
| SCHEMBL17993127 | 0.76 | MAPT (0.45) | MAPTTP53LMNACMA1GSK3A | |
| SCHEMBL19665355 | 0.75 | CMA1 (0.51) | MAPTTP53LMNACMA1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090246198-A1 | MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | claimed |
| WO-2009146034-A2 | MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | WO | disclosed |
| US-20090246198-A1 | MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090246198-A1 | MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246198-A1 | MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF | MAPK1, MAP3K1, MAP3K7 | MAPT 2128/4885TP53 705/4885LMNA 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.